

**Re: Your request made under the Freedom of Information Act 2000**

Q1. Does your trust or health board treat giant cell arteritis (GCA)? If not, please provide the name of the hospital or trust that you refer GCA patients to.  
Yes

Q2. In the past 3 months, how many patients with a primary diagnosis of GCA (ICD10 codes M31.5 or M31.6) were:  
Admitted as an inpatient  
Treated in A&E

**DATE RANGE:**

01/08/2023 to 31/10/2023

Month Admitted	Diagnosis Description	Treated In A&E	Admitted as an inpatient (Planned)	Grand Total
Aug	M315 Giant cell arteritis with polymyalgia rheumatica		1	1
<b>Aug Total</b>			<b>1</b>	<b>1</b>
Sep	M315 Giant cell arteritis with polymyalgia rheumatica		1	1
	M316 Other giant cell arteritis	4		4
<b>Sep Total</b>		<b>4</b>	<b>1</b>	<b>5</b>
Oct	M315 Giant cell arteritis with polymyalgia rheumatica		1	1
<b>Oct Total</b>			<b>1</b>	<b>1</b>
<b>Grand Total</b>		<b>4</b>	<b>3</b>	<b>7</b>

Q3. How many patients were treated by the rheumatology department in the past 3 months with the following:  
Tocilizumab – for any disease  
Tocilizumab for rheumatoid arthritis (RA) only  
Tocilizumab for giant cell arteritis (GCA) only

Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.

Q4. How many patients were treated by the ophthalmology department (for any disease) in the past 3 months with Tocilizumab?

0

Our Ref: 539/2023  
October 2023

Q5. How many patients were treated in A&E in the past 3 months for giant cell arteritis (GCA) with Tocilizumab?

0 patients (we have only been able to answer this as there have been no patients treated in A&E with Tocilizumab at all in this time period, pharmacy do not store diagnosis data.)